The Quality of Life During Intravesical Bacillus Calmette-Guerin Therapy

1996 ◽  
Vol 155 (4) ◽  
pp. 1221-1226 ◽  
Author(s):  
Andreas Bohle ◽  
Friedrich Balck ◽  
Jorn Von Wietersheim ◽  
Dieter Jocham
2002 ◽  
Vol 1 (1) ◽  
pp. 100
Author(s):  
Bernhard Planz ◽  
Thomas Deix ◽  
Horia Oltean ◽  
Anna Hammerer ◽  
Michael Marberger

1996 ◽  
pp. 1221-1226 ◽  
Author(s):  
Andreas Bohle ◽  
Friedrich Balck ◽  
Jorn Von Wietersheim ◽  
Dieter Jocham

Author(s):  
Keerthana Chandrasekar, ◽  
Tenzin Tsundue ◽  
Ponnusankar S

Vaccines are weakened or dead microbes injected for the development of an acquired immunity as a preventive measure, also including the use of microbial proteins. The spectrum of adverse events following vaccination has been increasing as well with increasing number of reports detailing the events following immunization. The rate of morbidity and mortality of many communicable diseases has significantly decreased with time with relieve to the quality of life as well as the overall pharma economic cost. In this case report vaccine-induced developmental delay was observed in a child of 16 months of age. The child was born with low birth weight despite which the child was administered with hepatitis B vaccine, poliomyelitis vaccine, and bacillus Calmette-Guerin within 24 h of birth. Consecutive clinical outcomes followed throughout the years, which induced a developmental delay in this child. This case clearly signifies the need for more evidence-based implementation for the management of various diseases at secondary care hospitals.


Author(s):  
Tenzin Tsundue ◽  
Ponnusankar S

Vaccines are weakened or dead microbes injected for the development of an acquired immunity as a preventive measure, also including the use of microbial proteins. The spectrum of adverse events following vaccination has been increasing as well with increasing number of reports detailing the events following immunization. The rate of morbidity and mortality of many communicable diseases has significantly decreased with time with relieve to the quality of life as well as the overall pharma economic cost. In this case report vaccine-induced developmental delay was observed in a child of 16 months of age. The child was born with low birth weight despite which the child was administered with hepatitis B vaccine, poliomyelitis vaccine, and bacillus Calmette-Guerin within 24 h of birth. Consecutive clinical outcomes followed throughout the years, which induced a developmental delay in this child. This case clearly signifies the need for more evidence-based implementation for the management of various diseases at secondary care hospitals.


Lupus ◽  
2009 ◽  
Vol 18 (13) ◽  
pp. 1213-1216 ◽  
Author(s):  
H. Orbach ◽  
A. Tanay

Vaccines are considered to be among the greatest medical discoveries, credited with the virtual eradication of some diseases and the consequent improved survival and quality of life of the at-risk population. With that, vaccines are among the environmental factors implicated as triggers for the development of inflammatory myopathies. The sporadic reports on vaccineinduced inflammatory myopathies include cases of hepatitis B virus, bacillus Calmette—Guérin, tetanus, influenza, smallpox, polio, diphtheria, diphtheria—pertussis—tetanus, combination of diphtheria with scarlet fever and diphtheria—pertussis—tetanus with polio vaccines. However, a significant increase in the incidence of dermatomyositis or polymyositis after any massive vaccination campaign has not been reported in the literature. In study patients with inflammatory myopathies, no recent immunization was recorded in any of the patients. Moreover, after the 1976 mass flu vaccination, no increase in the incidence of inflammatory myopathies was observed. Although rare, macrophagic myofasciitis has been reported following vaccination and is attributed to the aluminium hydroxide used as an adjuvant in some vaccines. Prospective multicenter studies are needed to identify potential environmental factors, including vaccines, as potential triggers for inflammatory myopathies. Lupus (2009) 18, 1213—1216.


1996 ◽  
Vol 156 (5) ◽  
pp. 1783-1783 ◽  
Author(s):  
A. Bohle ◽  
F. Balck ◽  
J. von Wietersheim ◽  
D. Jocham

Sign in / Sign up

Export Citation Format

Share Document